Education and Training
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Exosurf
- drug: Survanta
Eligibility
Inclusion Criteria:
- Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
receiving assisted ventilation with 30% oxygen or more
Exclusion Criteria:
- Less than 6 hours of age
Ages Eligible for Study
N/A - 6 Hours
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting